Cosmetic composition of liquid crystalline lipid particles

Abstract

The invention claimed herein relates to liquid crystalline lipid particles which are substantially free of ethoxylated emulsifiers without compromising skin and / or hair care performance. The liquid crystalline lipid particles of the present invention can provide skin protection benefits.

Description

Technical Field

[0001] The invention claimed herein relates to liquid crystal lipid particles that are substantially free of ethoxylated emulsifiers. In particular, the invention claimed herein relates to liquid crystal lipid particles for use in topical compositions. Topical compositions containing liquid crystal lipid compositions offer benefits such as high moisturizing efficacy, excellent skin feel, skin softness, and skin smoothness. Background Technology

[0002] The skin plays a vital role as a barrier membrane, preventing the loss of essential biological components such as water, and protecting it from external biological, chemical, or physical aggressors such as microorganisms, chemicals, and ultraviolet radiation. The stratum corneum, approximately 20 μm thick and located in the outermost layer of the skin, is the part that functions as a barrier membrane. It is composed of stacked keratinocytes linked together by intercellular lipids that act as mortar, forming a robust barrier membrane.

[0003] The stratum corneum provides an important barrier function, the most important of which is preventing excessive transepidermal water loss (“TEWL”). In addition to delaying TEWL, the thin membrane of lipid layers also protects against the invasion of foreign chemicals and microorganisms.

[0004] Emulsifiers that form lamellar liquid crystals are being marketed by cosmetic ingredient suppliers as a mimicry of the multilayered lipid structure of the stratum corneum.

[0005] In the cosmetics industry, smaller particles are believed to be more easily absorbed into the skin and repair damage more readily and efficiently. The integration of nanotechnology into cosmeceuticals aims to extend the fragrance of perfumes, protect the skin in sunscreens, combat aging in anti-aging creams, and retain skin moisture in moisturizers. Some nanotechnology-based innovations include nanoemulsions (which are transparent and possess unique tactile and texture properties), nanocapsules (used in skincare products), nanopigments (which are transparent and enhance the efficiency of sunscreens), liposome formulations (containing small vesicles composed of conventional cosmetic materials that protect against oxygen-sensitive or photosensitive cosmetic ingredients), niosomes, nanocrystals, solid lipid nanoparticles, carbon nanotubes, fullerenes, and dendritic polymers. The main advantages of using nanoparticles in cosmeceuticals include improved stability of cosmetic ingredients (e.g., vitamins, unsaturated fatty acids, and antioxidants) by encapsulating them within nanoparticles; highly effective protection of the skin from harmful ultraviolet (UV) rays; aesthetically pleasing products (e.g., in mineral sunscreens, the use of smaller active mineral particles prevents them from leaving noticeable white marks upon application); targeted targeting of active ingredients to desired areas; and controlled release of active ingredients to prolong the effect.

[0006] WO 2020 / 156983 discloses liquid crystal lipid particles for use in topical compositions to reduce dust adhesion to the skin. WO 2021 / 005104 also discloses liquid crystal lipid particles for hair conditioning. Both prior art documents disclose liquid crystal lipid particles containing ethoxylated emulsifiers. Ethoxylated emulsifiers may raise concerns due to the presence of 1,4-dioxane as a byproduct, which has been reported to be potentially carcinogenic.

[0007] Therefore, there remains a need for a cosmetic composition or skin care composition comprising liquid crystal lipid particles that are substantially free of ethoxylated emulsifiers and do not impair skin and / or hair care performance. Summary of the Invention

[0008] Surprisingly, the liquid crystal lipid particles of the present invention not only provide skin protection using lipid nanoparticle technology, but are also environmentally and health-friendly, and exhibit good stability for safe consumer use. In particular, the liquid crystal lipid particles of the present invention exhibit good formulation stability, moisturizing effects, cleansing effects, anti-dust adhesion effects, anti-permeability effects, and good film-forming properties.

[0009] The liquid crystal lipid particles of the present invention comprise compounds (I) to (V).

[0010] (I) At least one compound having the general formula (I),

[0011]

[0012] General formula (I),

[0013] Where a is an integer in the range of ≥ 10 to ≤ 24.

[0014] (II) At least one compound having the general formula (II),

[0015]

[0016] General formula (II),

[0017] Where x is an integer in the range ≥ 10 to ≤ 24, and y is an integer in the range ≥ 10 to ≤ 25.

[0018] (III) At least one compound having the general formula (III),

[0019]

[0020] General formula (III),

[0021] Where p is an integer in the range of ≥ 10 to ≤ 20.

[0022] (IV) At least one anionic surfactant selected from the group consisting of alkyl glutamate surfactants, alkyl sulfosuccinate surfactants, and alkyl phosphate surfactants, preferably the at least one anionic surfactant being an alkyl glutamate surfactant, and

[0023] (V) At least one sucrose with C 12-30 Fatty acid esters.

[0024] The liquid crystal lipid particles of the present invention are substantially free of ethoxylated emulsifiers.

[0025] In another aspect, the present invention relates to a topical composition comprising liquid crystal lipid particles as defined above. Detailed Implementation

[0026] Before describing the inventive compositions and formulations of the invention claimed herein, it should be understood that the invention is not limited to the specific compositions and formulations described, as such compositions and formulations can naturally vary. It should also be understood that because the scope of the invention claimed herein will be defined only by the appended claims, the terminology used herein is not intended to be restrictive.

[0027] If a group is defined below as including at least a certain number of embodiments, this means that it also includes a group preferably consisting only of those embodiments. Furthermore, the terms 'first,' 'second,' 'third' or 'a', 'b', 'c', etc., in the specification and claims are used to distinguish between similar elements and are not necessarily used to describe a sequential or chronological order. It should be understood that the terms thus used are interchangeable where appropriate, and the embodiments of the invention claimed herein can be operated in any order other than that described or shown herein. Where the terms 'first,' 'second,' 'third' or '(A)', '(B)' and '(C)' or '(a)', '(b)', '(c)', '(d)', 'i', 'ii', etc., relate to steps of a method, use, or experiment, unless otherwise indicated in the application as described above or below, there is no temporal or time interval continuity between these steps; that is, these steps may be performed simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks, months, or even years between such steps.

[0028] Furthermore, the scope defined throughout this specification also includes end values; that is, the range of 1 to 10 means that both 1 and 10 are included within this range. For the avoidance of doubt, the applicant is entitled to any equivalent under applicable law.

[0029] The following paragraphs define in more detail the different aspects of the invention claimed herein. Each aspect so defined may be combined with any one or more other aspects unless explicitly indicated otherwise. In particular, any feature indicated as preferred or advantageous may be combined with any one or more other features indicated as preferred or advantageous.

[0030] Throughout this specification, references to 'one embodiment' or 'an embodiment' mean that a specific feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention claimed herein. Therefore, the phrase 'in one embodiment' appearing in different places throughout this specification does not necessarily refer to the same embodiment, but may refer to the same embodiment. Furthermore, in one or more embodiments, specific features, structures, or characteristics may be combined in any suitable manner, as will be apparent to those skilled in the art from this disclosure. Moreover, although some embodiments described herein include some but not others included in other embodiments, combinations of features from different embodiments are intended to be within the scope of the invention claimed herein and form different embodiments, as will be understood by those skilled in the art. For example, in the appended claims, any of the claimed embodiments can be used in any combination.

[0031] "Topical application" means applying or spreading the composition directly onto the skin surface of a human or animal body, preferably onto the face, scalp, feet, limbs, or torso. Specifically, for the purposes of this invention, topical application preferably means a cosmetic composition or skin care composition.

[0032] As used herein, the terms “free of,” “substantially free of,” “free from,” and / or “substantially free from” mean a composition that is completely lacking in the component or a composition having such a small amount of the component that the component may be present in amounts of less than 0.5%, less than 0.1%, or less than 0.01% by weight.

[0033] The invention claimed herein relates to the use of liquid crystal lipid particles in cosmetic or skin care compositions.

[0034] The liquid crystal lipid particles of the invention claimed herein, which are substantially free of ethoxylated emulsifiers, comprise compounds (I) to (V), which contain,

[0035] (I) At least one compound having the general formula (I):

[0036]

[0037] General formula (I),

[0038] Where a is an integer in the range of ≥ 10 to ≤ 24.

[0039] (II) At least one compound having the general formula (II):

[0040]

[0041] General formula (II),

[0042] Where x is an integer in the range ≥ 10 to ≤ 24, and y is an integer in the range ≥ 10 to ≤ 25.

[0043] (III) At least one compound having the general formula (III):

[0044]

[0045] General formula (III),

[0046] Where p is an integer in the range of ≥ 10 to ≤ 20.

[0047] (IV) At least one anionic surfactant selected from the group consisting of alkyl glutamate surfactants, alkyl sulfosuccinate surfactants, and alkyl phosphate surfactants, preferably alkyl glutamate surfactants, and

[0048] (V) At least one sucrose with C 12-30 Fatty acid esters.

[0049] In another embodiment of the invention, the topical composition of the invention comprises at least one liquid crystal lipid particle as defined above.

[0050] In embodiments of the invention claimed herein, in the at least one compound having general formula (I)

[0051]

[0052] General formula (I),

[0053] a is an integer in the range of ≥ 10 to ≤ 24.

[0054] In embodiments of the invention claimed herein, the at least one compound having general formula (I) is selected from the group consisting of: glyceryl stearate, glyceryl laurate and glyceryl palmitate, glyceryl caprylate, and glyceryl myristate.

[0055] In a preferred embodiment of the invention claimed herein, the at least one compound having general formula (I) is glyceryl stearate.

[0056] In embodiments of the invention claimed herein, in the at least one compound having general formula (II),

[0057]

[0058] General formula (II),

[0059] x is an integer in the range ≥ 10 to ≤ 24, and y is an integer in the range ≥ 10 to ≤ 25.

[0060] In embodiments of the invention claimed herein, the at least one compound having general formula (II) is selected from the group consisting of: myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl benzyl acid, myristyl erucic acid, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl benzyl acid, cetyl erucic acid, stearyl myristate, stearyl palmitate, stearyl stearate, stearyl isostearate, stearyl oleate, stearyl benzyl acid, stearyl erucic acid, isostearyl myristate, myristyl palmitate, stearyl palmitate, stearyl stearate, stearyl isostearate, myristyl palmit ... Isostearyl palmitate, isostearyl stearate, isostearyl isostearyl oleate, isostearyl benzyl acid, isostearyl oleate, myristate oleate, palmitic acid oleate, stearic acid oleate, isostearyl isostearyl oleate, oleic acid oleate, benzyl acid oleate, erucic acid oleate, myristate benzyl palmitate, palmitic acid benzyl stearate, isostearyl isostearyl oleate, benzyl acid benzyl oleate, benzyl oleate, myristate benzyl palmitate, palmitic benzyl palmitate, stearic acid benzyl palmitate, isostearyl palmitate, oleic acid benzyl palmitate, benzyl palmitate, and erucic acid benzyl palmitate.

[0061] In another embodiment of the invention claimed herein, the at least one compound having the general formula (II) is selected from the group consisting of cetyl palmitate, myristyl myristate, tetradecyl tetradecanoate, and betaine.

[0062] In a preferred embodiment of the invention claimed herein, the at least one compound having general formula (II) is selected from the group consisting of cetyl palmitate and myristyl myristate. In a preferred embodiment of the invention, the compound having general formula (II) is a combination of cetyl palmitate and myristyl myristate.

[0063] In embodiments of the invention claimed herein, in the at least one compound having general formula (III),

[0064]

[0065] General formula (III),

[0066] p is an integer in the range of ≥ 10 to ≤ 20.

[0067] In yet another embodiment of the invention claimed herein, the at least one compound having general formula (III) is selected from the group consisting of lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmoleyl alcohol, heptadecanol, stearyl alcohol, arachidyl alcohol, and betaine alcohol or mixtures thereof.

[0068] In a preferred embodiment of the invention claimed herein, the at least one compound having general formula (III) is selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, or mixtures thereof.

[0069] In the most preferred embodiment of the invention claimed herein, the at least one compound having general formula (III) is a mixture of cetyl alcohol and stearyl alcohol.

[0070] In one embodiment of the invention, the at least one compound (IV) alkyl glutamate surfactant is selected from the group consisting of sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate, and sodium stearoyl glutamate. Preferably, the at least one alkyl glutamate surfactant is sodium stearoyl glutamate.

[0071] In one embodiment of the invention, the liquid crystal lipid particles of the invention claimed herein comprise at least one sucrose and C 12-30Esters of fatty acids (compound V). Specific examples include sucrose distearate or sucrose tristearate, sucrose cocoate, sucrose dilaurate, sucrose distearate, sucrose hexasorcinate, sucrose hexapalmitate, sucrose laurate, sucrose mortierellate, sucrose myristate, sucrose oleate, sucrose palmitate, sucrose pentasorcinate, sucrose polysuccinate, sucrose polystigmate, sucrose polystigmate, sucrose polylinoleate, sucrose polyoleate, sucrose polypalmitate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose tetraisostigmate, and sucrose trilaurate. Suitable examples include mixtures of stearic acid and sucrose esters (sucrose polystigmate) commercially available from BASF.

[0072] In embodiments of the invention claimed herein, the crystalline lipid particles comprise glyceryl stearate, cetyl palmitate and / or myristyl myristate, cetyl alcohol, stearyl alcohol, sodium stearoyl glutamate and sucrose polystearate.

[0073] In embodiments of the invention claimed herein, the crystalline lipid particles comprise glyceryl stearate, myristyl myristate, cetyl alcohol, stearyl alcohol, sodium stearoyl glutamate, and sucrose polystearate.

[0074] In embodiments of the invention claimed herein, the liquid crystal lipid particles have an average particle size of ≥ 20 nm to ≤ 500 nm, as determined using dynamic light scattering with a Malvern DLS ZS90.

[0075] In embodiments of the invention claimed herein, the liquid crystal lipid particles have an average particle size of ≥ 20 nm to ≤ 300 nm, as determined using dynamic light scattering with a Malvern DLS ZS90.

[0076] In embodiments of the invention claimed herein, the liquid crystal lipid particles have an average particle size of ≥ 100 nm to ≤ 250 nm, as determined using dynamic light scattering with a Malvern DLS ZS90.

[0077] In embodiments of the invention claimed herein, the liquid crystal lipid particles have average particle sizes of 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm or 200 nm, 210 nm, 220 nm, 230 nm, 240 nm, 250 nm, as determined using dynamic light scattering with a Malvern DLS ZS90.

[0078] In embodiments of the invention claimed herein, liquid crystal lipid particles are prepared by using an emulsion via high-pressure homogenization.

[0079] In embodiments of the invention claimed herein, the liquid crystal lipid particles have a hexagonal and / or orthogonal lateral stacking.

[0080] In embodiments of the invention claimed herein, liquid crystal lipid particles are contained in a topical composition for application to skin and / or hair.

[0081] In embodiments of the invention claimed herein, liquid crystal lipid particles form a matrix for use in any topical composition applied to the skin and / or hair.

[0082] In some embodiments, the liquid crystal lipid particles may contain one or more conventional preservatives, including benzalkonium chloride, benzyl chloride, benzyl alcohol, chlorophenoxyethanol, diazolidinyl urea, ethylenediaminetetraacetic acid, ethylparaben, imidazolidinyl urea, methylparaben, phenoxyethanol, linoleamide propyl PG-dimethylammonium chloride phosphate, cocamidopropyl PG-dimethylammonium chloride phosphate, propylparaben, cis-1-(3-chloroallyl)-3,5,7-triaza-1-azadamane adamantane chloride, dehydroacetic acid or its salts, benzoic acid or its salts, sodium hydroxymethylglycinate, and zinc pyrithione. However, in some preferred embodiments, the liquid crystal lipid particles of the present invention are substantially free of conventional preservatives, including benzalkonium chloride, benzyl chloride, benzyl alcohol, chlorophenoxyacetate, diazolidinyl urea, ethylenediaminetetraacetic acid, ethylparaben, imidazolidinyl urea, methylparaben, phenoxyethanol, linoleamide propyl PG-dimethylammonium chloride phosphate, cocamidopropyl PG-dimethylammonium chloride phosphate, propylparaben, cis-1-(3-chloroallyl)-3,5,7-triaza-1-azadamane adamantane chloride, dehydroacetic acid or its salts, benzoic acid or its salts, sodium hydroxymethylglycinate, and zinc pyrithione. The liquid crystal lipid particles contain only a combination of pentylene glycol with at least one of glyceryl caprylate and hydroxyacetophenone, and optionally at least one of dioctanoyl hydroxamic acid and octanediol, which can achieve satisfactory antimicrobial effects.

[0083] In embodiments of the invention claimed herein, the liquid crystal lipid particles are present in an amount ranging from ≥ 0.1% to ≤ 30% by weight based on the total weight of the topical composition. In another embodiment of the invention claimed herein, the at least one liquid crystal lipid particle is present in an amount ranging from ≥ 1% to ≤ 25% by weight based on the total weight of the composition. In a preferred embodiment of the invention claimed herein, the at least one liquid crystal lipid particle is present in an amount ranging from ≥ 1% to ≤ 20% by weight based on the total weight of the composition. In the most preferred embodiment of the invention claimed herein, the at least one liquid crystal lipid particle is present in an amount ranging from ≥ 1% to ≤ 15% by weight based on the total weight of the composition.

[0084] In a preferred embodiment, the topical composition may further comprise additional nonionic emulsifiers or anionic emulsifiers, such as suitable anionic emulsifiers selected from the group consisting of sodium stearoyl glutamate, sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate, potassium cocoyl glutamate, potassium lauroyl glutamate, and combinations thereof.

[0085] In embodiments of the invention claimed herein, the topical composition is present in the form of a cream, foam, lotion, gel, paste, spray, patch, spray patch, mousse, or ointment.

[0086] In embodiments of the invention claimed herein, the cosmetic composition further comprises at least one adjuvant selected from the group consisting of: anti-wrinkle active agents, anti-acne active agents, emulsifiers, antioxidants, emollients, self-tanning active agents, skin whitening agents, sunscreens, UV absorbers, thickeners, humectants, abrasives, absorbents, fragrances, buffers, sunscreens, colorants, preservatives, fillers, pH adjusters, and solvents.

[0087] In embodiments of the invention claimed herein, the active agent is selected from the group consisting of: anti-wrinkle agents such as retinol, hyaluronic acid, ceramide, niacinamide, vitamin E, alpha hydroxy acids, and anti-acne agents such as clindamycin, bemaconazole, benzoyl peroxide, and isotretinoin.

[0088] In embodiments of the invention claimed herein, the skin whitening agent is selected from the group consisting of: retinoic acid, hydroquinone, resorcinol, arbutin, kojic acid, azelaic acid, vitamin C, glutathione, and alpha-hydroxy acids.

[0089] In embodiments of the invention claimed herein, the topical composition may further comprise at least one thickener. The thickener may be selected from the group consisting of polymeric thickeners (including nonionic and anionic thickeners, or mixtures thereof). Suitable nonionic thickeners include polyacrylamide polymers, crosslinked poly(N-vinylpyrrolidone), polysaccharides, natural or synthetic gums or polysaccharides, polyvinylpyrrolidone, and polyvinyl alcohol. Suitable anionic thickeners include polyacrylates, acrylate / ethyl acrylate copolymers, carboxyvinyl polymers, and crosslinked copolymers of alkyl vinyl ethers and maleic anhydride.

[0090] In embodiments of the invention claimed herein, the thickener is selected from the group consisting of: polysaccharides, including cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate, hydroxyethyl cellulose, hydroxyethyl ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof; natural gums, such as gum arabic, agar, alginic acid, ammonium alginate, amylopectin, calcium alginate, carrageenan calcium, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, etc. The following are included: guar hydroxypropyltrimethylammonium chloride, lithium montmorillonite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar gum, ark tartar gum, seaweed, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. Preferably, the thickener is selected from the group consisting of xanthan gum, succinosaccharide, gellan gum, pectin, alginate, starch, guar gum, acrylates, acrylate copolymers, carbomer, and associative thickeners. According to any embodiment of the invention, the thickener is present in an amount ranging from ≥ 0.1% to ≤ 5% by weight based on the total weight of the topical composition.

[0091] In embodiments of the invention claimed herein, the wetting agent is selected from the group consisting of: sodium 2-pyrrolidone-5-carboxylate (NaPCA), guanidine, glycolic acid and glycolates (e.g., ammonium and quaternary alkylammonium), lactic acid and lactates (e.g., ammonium or quaternary alkylammonium), aloe vera in any of its various forms (e.g., aloe vera gel), hyaluronic acid and its derivatives (e.g., salt derivatives such as sodium hyaluronate), lactamide monoethanolamine, acetamide monoethanolamine, urea, panthenol and its derivatives, and mixtures thereof.

[0092] In embodiments of the invention claimed herein, the buffer is selected from the group consisting of: lactic acid, lactate, gluconic acid, gluconic acid-δ-lactone, sodium gluconate and potassium gluconate, trisodium citrate, tripotassium citrate, sodium lactate and potassium lactate.

[0093] In embodiments of the invention claimed herein, the solvent is selected from the group consisting of: polyols including glycerol, diglycerol, triglyceride, polyglycerol, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexanediol, 1,3-butanediol, 1,4-butanediol, ethylene glycol monoalkyl ethers, diethylene glycol monoalkyl ethers, glucose, maltose, sucrose, lactose, xylose, xylitol, sorbitol, mannitol, maltitol, maltitol, panthenol, pentaerythritol, and hyaluronic acid and their salts; water; ethanol and isopropanol.

[0094] In embodiments of the invention claimed herein, the solvent is selected from the group consisting of glycerol, water, and ethanol.

[0095] In embodiments of the invention claimed herein, liquid crystal lipid particles are contained in a topical composition, which further comprises a sunscreen, a UV absorber, a thickener, and a solvent.

[0096] In a preferred embodiment of the invention claimed herein, liquid crystal lipid particles are contained in a topical composition that further comprises diethylaminohydroxybenzoylhexylbenzoate, ethylhexyl methoxycinnamate, acrylate / benzyl alcohol polyether-25 methacrylate copolymer, methylene bis-benzotriazolyl tetramethylbutylphenol, decyl glucoside, propylene glycol and xanthan gum, ethanol, water and butanediol.

[0097] According to any embodiment of the invention, the topical composition further comprises a carrier or a mixture of such carriers suitable for application to skin and / or hair. Suitable carriers for use in the topical composition include water, C1-C6 alcohols, lower alkyl acetates, and mixtures thereof. In some embodiments, the carrier may also contain a variety of additional materials such as acetone, hydrocarbons (e.g., isobutane, hexane, decene, halogenated hydrocarbons), and volatile silicones (e.g., cyclomethylsiloxanes). In one embodiment, water is present in the topical composition in an amount ranging from ≥ 5% to ≤ 80% by weight based on the total weight of the topical composition.

[0098] The compositions of the present invention are used in a manner suitable for the intended end use of the product. For example, when treating occasional dry skin caused by exposure to climate or other temporary conditions, or when treating occasional skin irritation, the compositions may be used as needed until the condition is relieved. When used to treat more persistent conditions, such as those associated with lipid barrier defects or insufficiency (especially sensitive skin), dry skin associated with any type of aging, or wrinkles or fine lines associated with thinning of the stratum corneum with aging, long-term application of the compositions is preferred to prevent recurrence of the condition.

[0099] In the embodiments, the composition of the invention claimed herein can be used at about 0.1 mg / cm³. 2 skin up to 2 mg / cm 2 Apply to the skin approximately once a week to approximately four or five times a day, preferably approximately three times a week to approximately three times a day, and most preferably approximately once or twice a day.

[0100] Furthermore, the compositions of the invention claimed herein can be applied for a longer duration, preferably for at least about one month, about three months to about twenty years, more preferably about six months to about ten years, and still more preferably about one year to about five years, thereby resulting in treatment or prevention of the disease in question. Example

[0101] The following examples illustrate the methods and results based on the disclosed subject matter. These examples are not intended to include all aspects of the subject matter disclosed herein, but rather to illustrate representative methods, compositions, and results. These examples are not intended to exclude equivalents and variations of the invention claimed herein, which will be apparent to those skilled in the art.

[0102] Material:

[0103] From BASF:

[0104] •Cutina ® GMS V: Glyceryl stearate.

[0105] •Eumulgin ® SG: Sodium stearoyl glutamate.

[0106] •Lanette ® O: Cetearyl alcohol.

[0107] •Cetiol ® MM: Myristyl myristate.

[0108] •Emulgade ® Sucro Plus: 80%-95% sucrose polystearate (and 5%-20% cetyl palmitate).

[0109] •Emulgade ® Verde 10 MS: Polyglycerol-10 stearate.

[0110] •Eumulgin ® Prisma: Disodium cetearyl sulfosuccinate.

[0111] •Cremophor ®GS 32: Polyglycerol-3 distearate.

[0112] •Emulgade ® 68 / 50: 40%-60% cetearyl glucoside (and) 40%-60% cetearyl alcohol.

[0113] •Cosmeida ® SP: Sodium polyacrylate.

[0114] •Verdessence TM Xanthan gum: Xanthan gum.

[0115] •Uvinul ® A Plus: Diethylaminohydroxybenzoylhexylbenzoate.

[0116] •Uvinul ® MC 80: Ethylhexyl methoxycinnamate.

[0117] •Tinosorb ® M: 48%-52% methylenebisbenzotriazolyltetramethylbutylphenol, 36.9%-45.7% water, 6.0%-10.0% decyl glucoside, 0.2%-0.6% propylene glycol and 0.1%-0.5% xanthan gum.

[0118] •Tinovis ® GTC UP: 28%-33% acrylate / sobyl alcohol polyether-25 methacrylate copolymer and 65%-75% water.

[0119] Neutrol ® TE: Tetrahydroxypropylethylenediamine.

[0120] From Willmar:

[0121] • Glycerin RG-995: Glycerin.

[0122] From Inolex:

[0123] •Lexgard ® GMCY MB: Caprylic / Capric Glyceryl Acetate.

[0124] •Spectrastat TM G2 natural MB: Capryloyl hydroxamic acid (and) caprylic acid glyceride (and) glycerol.

[0125] From Symrise:

[0126] •Hydrolite ®5. Green: Pentylene glycol.

[0127] •Symsave TM H: Hydroxyacetophenone.

[0128] From Minasolve:

[0129] •A-Leen 8: Octadiol.

[0130] From Schulke:

[0131] •EUXYL® PE9010: 90% phenoxyethanol (and) 10% ethylhexylglycerin.

[0132] From Shanghai YouZhu Industry Company Ltd.

[0133] • Sodium hydroxide: Sodium hydroxide (32%) and water.

[0134] • Butanediol: 1,3-Butanediol.

[0135] Experimental section:

[0136] pH measurement: The pH of the liquid crystal lipid particle raw material was measured using a FiveEasy Plus pH meter from Mettler Toledo.

[0137] Viscosity measurement: The viscosity of the liquid crystal lipid particle raw material was measured by Brookfield.

[0138] Particle size measurement: The particle size of the liquid crystal lipid particles was measured using a Malvern DLS ZS90.

[0139] instrument:

[0140] Homogenizer: Eurostar 20 Digital IKA

[0141] High-pressure homogenizer: ATS AH-1500

[0142] Test 1: Stability test compared with other natural, non-ethoxylated nonionic emulsifiers / surfactants.

[0143]

[0144] qs = appropriate amount; a Based on the volume of commercial products.

[0145] Manufacturing method:

[0146] 1. Heat part A to 50°C and stir the mixture at 400 rpm until a uniform grayish-white emulsion (lotion) is obtained.

[0147] 2. Maintain the stirring speed at 400 rpm and heat the mixture to 78°C ± 2°C. Keep stirring at 78°C ± 2°C for 5 min, until a uniform off-white to slightly pale yellow emulsion is formed.

[0148] 3. Cool at 300 rpm with stirring. Add part B to the mixture at 65°C. Continue stirring at 65°C for 3 minutes.

[0149] 4. Add part of C to the mixture at 50°C and keep stirring at 300 rpm for 3 min until a grayish-white to slightly pale yellow emulsion is formed.

[0150] 5. Add some D to adjust the pH to 9.0-9.30.

[0151] 6. Perform high-pressure homogenization for 3 cycles at a pressure of 800 ± 50 bar.

[0152] result:

[0153]

[0154] Examples of the present invention during long-term storage Ex.1B1 The stability was satisfactory for 3 months at -20°C / 4°C / 25°C / 40°C and for 1 month at 50°C. All samples exhibited a uniform grayish-white emulsion at different times, as shown in Figure 1. However, Comparison 1 , Comparison 2 and Comparison 3 As shown in Figure 2- Figure 4 The partial separation or gelatinous, unstable appearance shown is deemed unacceptable. Therefore, Example Ex.1B1 Shows a ratio Comparison 1 , Comparison 2 and Comparison 3 Better stability.

[0155] The result is Figure 1 to Figure 4 As shown in the image.

[0156] Test 2: Comparison of antimicrobial tests

[0157]

[0158] qs = appropriate amount; a Based on the volume of commercial products

[0159] Manufacturing method:

[0160] 1. Heat part A to 50°C and stir the mixture at 400 rpm until a uniform grayish-white emulsion is obtained.

[0161] 2. Maintain the stirring speed at 400 rpm and heat the mixture to 78°C ± 2°C. Continue stirring at 78°C ± 2°C for 5 minutes until a uniform, off-white to slightly pale yellow emulsion is obtained.

[0162] 3. Cool at 300 rpm with stirring. Add part B to the mixture at 65°C. Continue stirring at 65°C for 3 minutes.

[0163] 4. Add part of C to the mixture at 50°C and keep stirring at 300 rpm for 3 min until a grayish-white to slightly pale yellow emulsion is formed.

[0164] 5. Add some D to adjust the pH to 9.0-9.30.

[0165] 6. Perform high-pressure homogenization for 3 cycles at a pressure of 800 ± 50 bar.

[0166] result:

[0167]

[0168]

[0169]

[0170] 1. Heat part A to 50°C and stir the mixture at 400 rpm until a uniform grayish-white emulsion is obtained.

[0171] 2. Maintain the stirring speed at 400 rpm and heat the mixture to 78°C ± 2°C. Continue stirring at 78°C ± 2°C for 5 minutes until a uniform, off-white to slightly pale yellow emulsion is obtained.

[0172] 3. Cool at 300 rpm with stirring. Add part B to the mixture at 65°C. Continue stirring at 65°C for 3 minutes.

[0173] 4. Add part of C to the mixture at 50°C to adjust the pH, and keep stirring at 300 rpm for 3 min until a grayish-white to slightly pale yellow emulsion is formed.

[0174] 5. Perform high-pressure homogenization for 3 cycles at a pressure of 800 ± 50 bar.

[0175] result:

[0176]

[0177] Regarding microbial stability, all the above examples passed the challenge test based on the method of European Pharmacopoeia 10.0 5.1.3.

[0178] Test 4: Film Formation Effect of Liquid Crystal Products (Test Plan as follows):

[0179]

[0180] qs = appropriate amount

[0181] Manufacturing methods and testing procedures:

[0182] 1. Heat part A to 80°C and stir evenly.

[0183] 2. Cool to 45°C and add part of B and stir evenly.

[0184] 3. Pre-disperse some of the C and add it to the mixture, stirring thoroughly.

[0185] 4. Adjust the pH to 6.0-6.5 using a portion of the D.

[0186] 5. The film formation status of the sample was tested using a WLI-3D profilometer.

[0187] result:

[0188]

[0189] The formulation Ex.2-2 obtained from liquid crystal particles can form a rough film of about 1 μm thickness, exhibiting excellent film-forming properties.

[0190] Test 5: Surface contaminant cleaning effect (test plan as follows):

[0191]

[0192] qs = appropriate amount

[0193] Manufacturing method:

[0194] 1. Heat part A to 80°C and stir evenly.

[0195] 2. Cool to 45°C and add part of B and stir evenly.

[0196] 3. Pre-disperse some of the C and add it to the mixture, stirring thoroughly.

[0197] 4. Adjust the pH to 6.0-6.5 using a portion of the D.

[0198] Test protocol for cleaning surface contaminants:

[0199] 1. A total of four test areas (5 × 5 cm) on the volunteers' forearms were used to apply the test sample. Three areas used 100 μl of test sample Ex.3-1 and Ex.3-2, and one area served as a blank control.

[0200] 2. Take photos after drying for 15 minutes. These photos are then used to quantify anti-fouling performance through automated color evaluation.

[0201] 3. Each test area was then exposed to 30 mg of activated carbon powder by a continuous five-second air jet.

[0202] 4. After the contaminant application procedure, take another picture of the test area using the image recording box.

[0203] 5. Next, slowly and evenly pour 950 ml of warm water (> 38°C) onto the measurement area. Gently pat each test area dry with a tissue and take a new photo.

[0204] result:

[0205]

[0206] Example Ex.3-2 demonstrates the best surface contaminant cleaning effect compared to other examples, which is due to the liquid crystal particles of the present invention.

[0207] Test 6: Dust adhesion resistance (test plan as follows):

[0208]

[0209] qs = appropriate amount

[0210] Manufacturing method:

[0211] 1. Heat parts A and B separately to 80°C.

[0212] 2. Under homogenization, add part A to part B and mix until homogeneous.

[0213] 3. Add part C to the mixture of parts A and parts B and cool to 45°C.

[0214] 4. Add part D to the mixture and mix until homogeneous.

[0215] Test protocol for dust adhesion resistance:

[0216] 1. Apply 4 g test samples according to Examples Ex.4-1 and Ex.4-2 individually onto PMMA (polymethyl methacrylate) plates.

[0217] 2. Apply 2 g of test sample to the PMMA plate to ensure uniform distribution of the test sample on the plate.

[0218] 3. Place the PMMA plate in a 40°C oven for 30 minutes and then cool it at room temperature for 30 minutes.

[0219] 4. Attach 2 g of 5 μm standard sand from Sigma-Aldrich to a PMMA plate and then gently shake it upside down for 30 seconds.

[0220] 5. Invert the PMMA plate and weigh the sand in the petri dish.

[0221] result:

[0222]

[0223] The low dust adhesion rate in Example Ex.4-2 demonstrates the excellent performance of the liquid crystal particles.

[0224] Test 7: Permeability Resistance (Test Procedure as follows):

[0225]

[0226] qs = appropriate amount

[0227] Manufacturing method:

[0228] 1. Heat part A to 80°C and stir evenly.

[0229] 2. Cool to 45°C and add part of B and stir evenly.

[0230] 3. Pre-disperse some of the C and add it to the mixture, stirring thoroughly.

[0231] 4. Adjust the pH to 6.0-6.5 using a portion of the D.

[0232] Test procedure for impermeability:

[0233] 1. Apply fixed amounts of test samples Ex.5-1 and Ex.5-2 onto the artificial membrane.

[0234] 2. Allow the membrane to dry.

[0235] 3. Add the model pollutant fluorescent dye sodium fluorescein to the membrane and allow it to stand for a sufficient time, then measure the absorbance at 540 nm.

[0236] result:

[0237]

[0238] The low permeability in Example Ex.5-2 demonstrates the excellent anti-permeation ability of the liquid crystal particles.

[0239] Test 8: Moisturizing effect

[0240]

[0241] qs = appropriate amount

[0242] - Manufacturing method:

[0243] 1. Heat part A to 80°C and stir evenly.

[0244] 2. Cool to 45°C and add part of B and stir evenly.

[0245] 3. Pre-disperse some of the C and add it to the mixture, stirring thoroughly.

[0246] 4. Adjust the pH to 6.5-7.0 using a portion of the D.

[0247] Testing protocol for moisturizing effect:

[0248] 1. Twenty female volunteers aged 19-63 years (mean: 41.1%) were selected for this moisturizing effect test. Volunteers were instructed not to use any topical preparations on the test area from seven days before the test until the end of the test.

[0249] 2. Approximately 2 mg / cm 2 The test product was applied to the inside of the forearm for 30 seconds. Volunteers were instructed not to cover the test area with clothing for the first 20 minutes after application to ensure complete absorption, and to remove any residue with a soft tissue. Volunteers were also instructed to avoid physical activity and to avoid contact between the test area and water.

[0250] 3. Further measurements were performed at 2, 4, 8, and 24 hours after product application using a Corneometer MPA 5 CPU (Courge and Khazaka, Cologne, Germany) with a 7*7 mm probe tip. Five measurements were taken for each test area, and the mean (mean Corneometer reading - relative to baseline) was recorded and used to define the hydration status of the stratum corneum (Δskin hydration value).

[0251] 4. The measurement data are automatically processed by computer and analyzed using the ANOVA method.

[0252] 5. All measurements were performed under controlled environmental conditions of room temperature 21°C ± 1°C and relative humidity 45% ± 5%.

[0253] result:

[0254]

[0255] Compared to the basic formulation Ex.6-1, Ex.6-2, which contains the liquid crystal particles of the present invention, showed better moisturizing properties in all measurements within 24 hours after application.

Claims

1. A liquid crystal lipid particle comprising compounds (I) to (V), -(I) At least one compound (I) having the general formula (I): General formula (I), Where a is an integer in the range of ≥ 10 to ≤ 24. -(II) At least one compound (II) having the general formula (II): General formula (II), Where x is an integer in the range ≥ 10 to ≤ 24, and y is an integer in the range ≥ 10 to ≤ 25. -(III) At least one compound (III) having the general formula (III): General formula (III), Where p is an integer in the range of ≥ 10 to ≤ 20. -(IV) At least one anionic surfactant selected from the group consisting of alkyl glutamate surfactants, alkyl sulfosuccinate surfactants, and alkyl phosphate surfactants, preferably alkyl glutamate surfactants, and -(V) At least one sucrose with C 12-30 Fatty acid esters, These liquid crystal lipid particles are essentially free of ethoxylated emulsifiers.

2. The liquid crystal lipid particles according to claim 1, wherein, These liquid crystal lipid particles have a layered structure with hexagonal and / or orthogonal lateral stacking.

3. The liquid crystal lipid particles according to claim 1, wherein, These liquid crystal lipid particles have an average particle size in the range of ≥ 20 nm to ≤ 500 nm, as determined using dynamic light scattering with MalvernDLS ZS90.

4. The liquid crystal lipid particles according to any one of claims 1 to 3, wherein, The at least one compound having the general formula (I) is selected from the group consisting of glyceryl stearate, glyceryl laurate and glyceryl palmitate.

5. The liquid crystal lipid particles according to any one of claims 1 to 4, wherein, The at least one compound having the general formula (II) is selected from the group consisting of: cetyl palmitate, myristyl myristate, tetradecyl tetradecanoate, and betaine.

6. The liquid crystal lipid particles according to any one of claims 1 to 5, wherein, The at least one compound having the general formula (III) is selected from the group consisting of lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitol, heptadecanol, stearyl alcohol, or mixtures thereof.

7. The liquid crystal lipid particles according to any one of claims 1 to 6, wherein, The at least one anionic surfactant (IV) is an alkyl glutamate surfactant, preferably selected from the group consisting of sodium lauroyl glutamate, sodium cocoyl glutamate, sodium myristoyl glutamate, and sodium stearoyl glutamate.

8. The liquid crystal lipid particles according to any one of claims 1 to 7, wherein, This at least one sucrose and C 12-30 The fatty acid ester (V) is selected from the group consisting of: sucrose distearate or sucrose tristearate, sucrose cocoate, sucrose dilaurate, sucrose distearate, sucrose hexasucrate, sucrose hexapalmitate, sucrose laurate, sucrose oleate, sucrose myristate, sucrose oleate, sucrose palmitate, sucrose pentosucrate, sucrose polysuccinate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polylinoleate, sucrose polyoleate, sucrose polypalmitate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, sucrose polystigmate, and sucrose trilaurate, preferably sucrose polystigmate.

9. The liquid crystal lipid particles according to any one of claims 1 to 8, comprising glyceryl stearate, cetyl palmitate and / or myristyl myristate, cetyl alcohol, stearyl alcohol, sodium stearoyl glutamate and sucrose polystearate.

10. A topical composition comprising liquid crystal particles as defined in any one of claims 1 to 9.

11. The topical composition of claim 10, further comprising a combination of at least one of pentylene glycol and glyceryl caprylate and hydroxyacetophenone, and optionally at least one of dioctanoyl hydroxamic acid and octanediol, for achieving an antimicrobial effect.

12. The topical composition according to claim 10 or 11, wherein, The composition further comprises at least one thickener, preferably selected from the group consisting of xanthan gum, succinosaccharide, gellan gum, pectin, alginate, starch, guar gum, acrylate, acrylate copolymer, carbomer, and associative thickeners.

13. The topical composition according to any one of claims 10 to 12, wherein, The liquid crystal lipid particles are present in an amount ranging from ≥ 0.1% to ≤ 30% by weight based on the total weight of the topical composition.

14. The topical composition according to any one of claims 10 to 13, wherein, Water is present in an amount ranging from ≥ 5% to ≤ 80% by weight based on the total weight of the topical composition.

15. The topical composition according to any one of claims 10 to 14, further comprising at least one adjuvant selected from the group consisting of: anti-wrinkle active agents, anti-acne active agents, emulsifiers, antioxidants, emollients, self-tanning active agents, skin whitening agents, sunscreens, humectants, abrasives, absorbents, fragrances, buffers, sunscreens, colorants, preservatives, fillers, and pH adjusters.

16. The topical composition according to any one of claims 10 to 15, wherein, This topical composition is a skin care composition.

17. The topical composition according to any one of claims 10 to 16, wherein, The topical composition is available in the form of cream, foam, emulsion, gel, paste or ointment.

Images